Drugs / Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Autologous CD19/CD22 Chimeric Antigen Receptor T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04029038 | May 2019 → Nov 2022 | B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19/CD22 Chimeric Antigen Receptor T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04029038 ↗ |
| Modality | Cell therapy | “modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells” NCT04029038 ↗ |
| Route | Intravenous | “Given IV” NCT04029038 ↗ |